Progress in the diagnosis and treatment of connective tissue disease associated with immune thrombocytopenia
Immunological thrombocytopenia(ITP)is an immune-mediated disease,divided into primary ITP and secondary ITP.Connective tissue disease(CTD)is a group of systemic autoimmune diseases that mainly invade the whole body's connective tissue.It is the most common disease to combine with secondary ITP,including systemic lupus erythemato-sus,primary Sjogren syndrome,and antiphospholipid antibody syndrome.CTD-ITP patients have an increased tendency for bleeding,and in severe cases,it can lead to visceral bleeding with a high mortality rate,which is an important factor affect-ing the prognosis of CTD patients.In recent years,significant progress has been made in the research on the pathogenesis,clinical manifestations,and treatments of CTD-ITP.The use of new biological agents and platelet promoting drugs has benefi-ted patients more.Early diagnosis,grading of bleeding severity and risk assessment,as well as personalized and standardized treatment are key to achieve a good prognosis.
NETL
NSTL
万方数据
